Bristol Trial Lifts Depression Remission to 54% With Tocilizumab in 30 Patients
Updated
Updated · The Guardian · May 20
Bristol Trial Lifts Depression Remission to 54% With Tocilizumab in 30 Patients
4 articles · Updated · The Guardian · May 20
A 30-patient randomized trial at the University of Bristol found 54% of patients on tocilizumab reached depression remission, versus 31% on placebo, among people not helped by standard antidepressants.
Over four weeks, the anti-inflammatory drug also showed greater improvement across depression severity, fatigue, state anxiety and quality of life, though the small study produced limited statistical evidence for between-group differences.
Tocilizumab blocks the IL-6R receptor, testing an inflammation-based approach rather than the brain-chemical targets used by most current antidepressants.
Researchers said the number needed to treat was 5, compared with about 7 for SSRIs, suggesting immunotherapy could become a more tailored option for difficult-to-treat depression if larger trials confirm the findings.
Could an arthritis drug targeting inflammation become the future treatment for severe depression?
If your blood test shows inflammation, should you get immunotherapy instead of a traditional antidepressant?
Tocilizumab Shows Promise in First Randomized Trial for Treatment-Resistant Depression With Inflammation: A Precision Medicine Breakthrough
Overview
A groundbreaking pilot study by University of Bristol researchers has shown that tocilizumab, an anti-inflammatory drug, may offer new hope for people with treatment-resistant depression who have not improved with standard therapies. The study highlights how increased inflammation in the body is linked to depression that does not respond to usual treatments. By targeting this inflammation, tocilizumab opens up promising new treatment options. This progress is only possible thanks to dedicated research and the willingness of patients to participate in clinical trials, which together drive advancements in medicine and create new possibilities for those in need.